Contact Us
9101 N. Central Expwy.
Suite 600, Dallas, TX 75231
Tel: 214.827.2814
Location

Dr. Jejurikar's Blog

Get ready for a new competitor to Botox and Dysport. The FDA has approved Xeomin (incobotulinumtoxinA) for temporary treatment of glabellar frown lines (wrinkles between the eyebrows, otherwise known as the “elevens”).

Merz Aesthetics will distribute the product in the United States. According to a company statement, the approval is based on the results of two multicenter clinical trials involving 547 patients . In both studies, Xeomin injections significantly improved the appearance of glabellar frown lines in a month when compared with placebo. The product was not compared to Botox or Dysport.

Under a different brand name (Bocouture), Xeomin is already approved in 14 European countries. Merz officials says Xeomin will be available throughout the United States in the spring of 2012.

Comments are closed.

Contact

Contact

Our Location Dallas Plastic Surgery Institute

9101 N. Central Expwy.
Suite 600, Dallas, TX 75231
Tel: 214.827.2814
Dallas | Dr. Jejurikar

Stay Connected

Ready to get started?
Request a Consult